MALCOLM BRENNER to Animals
This is a "connection" page, showing publications MALCOLM BRENNER has written about Animals.
Connection Strength
1.120
-
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021 05 05; 29(5):1808-1820.
Score: 0.039
-
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res. 2018 01; 6(1):47-58.
Score: 0.031
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.031
-
Immunotherapy against cancer-related viruses. Cell Res. 2017 Jan; 27(1):59-73.
Score: 0.030
-
Improving the safety of T-Cell therapies using an inducible caspase-9 gene. Exp Hematol. 2016 Nov; 44(11):1013-1019.
Score: 0.029
-
A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy. Stem Cell Reports. 2015 Oct 13; 5(4):597-608.
Score: 0.027
-
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506.
Score: 0.027
-
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015 Aug 20; 126(8):983-92.
Score: 0.027
-
An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther. 2015 Sep; 23(9):1475-85.
Score: 0.027
-
Gene-modified cells for stem cell transplantation and cancer therapy. Hum Gene Ther. 2014 Jul; 25(7):563-9.
Score: 0.025
-
Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29.
Score: 0.024
-
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan; 257(1):107-26.
Score: 0.024
-
Is cancer gene therapy an empty suit? Lancet Oncol. 2013 Oct; 14(11):e447-e456.
Score: 0.024
-
Cellular therapy for cancer: let there be light. Tissue Antigens. 2012 Jan; 79(1):1-3.
Score: 0.021
-
T cell receptors and cancer: gain gives pain. Nat Med. 2010 May; 16(5):520-1.
Score: 0.019
-
Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010 Apr; 22(2):251-7.
Score: 0.018
-
The clone ranger? Mol Ther. 2008 Sep; 16(9):1520-1.
Score: 0.017
-
Developing T-cell therapies for cancer in an academic setting. Adv Exp Med Biol. 2008; 610:88-99.
Score: 0.016
-
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
Score: 0.013
-
Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies. Mol Ther. 2024 Aug 07; 32(8):2444-2460.
Score: 0.012
-
Antigen-induced regulatory T cells. Blood. 2004 Jul 01; 104(1):26-33.
Score: 0.012
-
Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Aug; 26(8):858-868.
Score: 0.012
-
Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann N Y Acad Sci. 2003 May; 996:80-8.
Score: 0.012
-
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4).
Score: 0.011
-
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790.
Score: 0.011
-
Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
Score: 0.011
-
Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation. Blood. 2003 Mar 15; 101(6):2434-9.
Score: 0.011
-
Cancer vaccines: dream, reality, or nightmare? Clin Exp Med. 2002 Nov; 2(3):109-18.
Score: 0.011
-
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
Score: 0.011
-
Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. Blood. 2002 Jul 01; 100(1):200-7.
Score: 0.011
-
Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther. 2002 Mar; 5(3):233-41.
Score: 0.011
-
Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy. Cytotherapy. 2022 03; 24(3):282-290.
Score: 0.010
-
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).
Score: 0.010
-
Gene transfer and the treatment of haematological malignancy. J Intern Med. 2001 Apr; 249(4):345-58.
Score: 0.010
-
Gene-marking studies of hematopoietic cells. Int J Hematol. 2001 Jan; 73(1):14-22.
Score: 0.010
-
To be or notch to be. Nat Med. 2000 Nov; 6(11):1210-1.
Score: 0.010
-
Transgenic CD8a? co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells. J Immunother Cancer. 2020 11; 8(2).
Score: 0.010
-
Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2).
Score: 0.010
-
Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
Score: 0.009
-
Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8a?-engineered human CD4+ T cells. Sci Adv. 2020 07; 6(27):eaaz7809.
Score: 0.009
-
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. 2020 05 06; 28(5):1251-1262.
Score: 0.009
-
Gene transfer by adenovectors. Blood. 1999 Dec 15; 94(12):3965-7.
Score: 0.009
-
"Resistance is futile". Gene Ther. 1999 Oct; 6(10):1646-7.
Score: 0.009
-
"The end of the beginning": molecular and cellular biology of gene therapy keystone. 14-20 January 1999. Biochim Biophys Acta. 1999 Jul 29; 1424(1):R5-9.
Score: 0.009
-
Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res. 1999 Jun; 23(6):549-57.
Score: 0.009
-
Fifth annual ISHAGE meeting - Oslo 1999. Cytotherapy. 1999; 1(3):163.
Score: 0.009
-
Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med. 1998 Nov; 4(11):1253-60.
Score: 0.008
-
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
Score: 0.008
-
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov. 2018 08; 8(8):972-987.
Score: 0.008
-
BMT beats autoimmune disease. Nat Med. 1998 Feb; 4(2):153-5.
Score: 0.008
-
Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther. 1997 Nov 01; 8(16):1935-43.
Score: 0.008
-
c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals. Blood. 2017 12 21; 130(25):2739-2749.
Score: 0.008
-
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26.
Score: 0.008
-
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Mol Ther. 2017 11 01; 25(11):2440-2451.
Score: 0.008
-
CD40 ligand induces an antileukemia immune response in vivo. Blood. 1997 Sep 01; 90(5):1927-33.
Score: 0.008
-
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247.
Score: 0.008
-
Antigen presentation: a balanced diet. Science. 1997 Jul 18; 277(5324):332.
Score: 0.008
-
Hematological malignancies. FASEB J. 1997 Jul; 11(8):640-8.
Score: 0.008
-
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
Score: 0.008
-
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051.
Score: 0.008
-
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
Score: 0.007
-
A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood. 1997 Jan 01; 89(1):119-27.
Score: 0.007
-
Gene marking. Hum Gene Ther. 1996 Oct 20; 7(16):1927-36.
Score: 0.007
-
Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 1996 Oct; 2(10):1090-5.
Score: 0.007
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
Score: 0.007
-
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther. 2016 Jun; 24(6):1135-1149.
Score: 0.007
-
Somatostatin as a trophic factor. Analysis of transgenic mice overexpressing somatostatin in astrocytes. Ann N Y Acad Sci. 1996 Mar 22; 780:29-35.
Score: 0.007
-
3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus. Biomaterials. 2016 Apr; 84:76-85.
Score: 0.007
-
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
Score: 0.007
-
The use of cytokines to improve gene transfer to human hematopoietic stem cells. Cytokines Mol Ther. 1995 Mar; 1(1):3-9.
Score: 0.007
-
Gene transfer into human hemopoietic progenitor cells. Br Med Bull. 1995 Jan; 51(1):167-91.
Score: 0.006
-
Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 2014 Nov; 21(11):472-482.
Score: 0.006
-
Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
Score: 0.006
-
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
Score: 0.006
-
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res. 2014 Jan 01; 20(1):131-9.
Score: 0.006
-
Mouse models in bone marrow transplantation and adoptive cellular therapy. Semin Hematol. 2013 Apr; 50(2):131-44.
Score: 0.006
-
Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia. Br J Haematol. 1992 Jun; 81(2):231-4.
Score: 0.005
-
IL-2 infusion abrogates humoral immune responses in humans. Clin Exp Immunol. 1992 Mar; 87(3):493-8.
Score: 0.005
-
Graft-versus-host reactions and bone-marrow transplantation. Curr Opin Immunol. 1991 Oct; 3(5):752-7.
Score: 0.005
-
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8.
Score: 0.005
-
IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol. 2010 Oct 01; 185(7):4223-32.
Score: 0.005
-
Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010 Sep; 12(5):576-8.
Score: 0.005
-
An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010 Jun; 28(6):1107-15.
Score: 0.005
-
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70.
Score: 0.005
-
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91.
Score: 0.004
-
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009 Sep 15; 15(18):5852-60.
Score: 0.004
-
Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009 Sep 12; 374(9693):912-20.
Score: 0.004
-
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402.
Score: 0.004
-
Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood. 1989 Apr; 73(5):1351-8.
Score: 0.004
-
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8.
Score: 0.004
-
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5.
Score: 0.004
-
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
Score: 0.004
-
IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther. 2007 Oct; 14(10):819-27.
Score: 0.004
-
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30.
Score: 0.004
-
Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol. 2007 Feb; 170(2):620-32.
Score: 0.004
-
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7.
Score: 0.004
-
CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul; 91(7):886-94.
Score: 0.004
-
Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006 May-Jun; 29(3):250-60.
Score: 0.004
-
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother. 2006 Jan-Feb; 29(1):21-31.
Score: 0.003
-
T cell therapies. Ernst Schering Found Symp Proc. 2006; (4):69-82.
Score: 0.003
-
An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54.
Score: 0.003
-
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood. 2005 Jun 15; 105(12):4677-84.
Score: 0.003
-
Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood. 2004 Oct 15; 104(8):2432-40.
Score: 0.003
-
Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids. Mol Ther. 2004 Apr; 9(4):489-95.
Score: 0.003
-
An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk Res. 2004 Mar; 28(3):295-9.
Score: 0.003
-
Primitive adult hematopoietic stem cells can function as osteoblast precursors. Proc Natl Acad Sci U S A. 2003 Dec 23; 100(26):15877-82.
Score: 0.003
-
American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther. 2003 Aug; 8(2):180-7.
Score: 0.003
-
Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther. 2003 Jun; 7(6):748-54.
Score: 0.003
-
Cells of the hepatic side population contribute to liver regeneration and can be replenished with bone marrow stem cells. Haematologica. 2003 Apr; 88(4):368-78.
Score: 0.003
-
hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. Genesis. 2001 Oct; 31(2):85-94.
Score: 0.003
-
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001 Aug 15; 98(4):1166-73.
Score: 0.003
-
Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther. 2000 Aug; 7(8):1120-6.
Score: 0.002
-
Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3. Blood. 1999 Sep 15; 94(6):1906-14.
Score: 0.002
-
Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene. Life Sci. 1999; 65(5):483-91.
Score: 0.002
-
Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism. Gene Ther. 1998 Dec; 5(12):1650-5.
Score: 0.002
-
Targeted deletion in astrocyte intermediate filament (Gfap) alters neuronal physiology. Proc Natl Acad Sci U S A. 1996 Jun 25; 93(13):6361-6.
Score: 0.002
-
Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. 1995 Dec; 2(4):291-7.
Score: 0.002
-
Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther. 1995 Sep; 6(9):1231-55.
Score: 0.002
-
European School of Oncology position paper. Gene therapy for the medical oncologist. Eur J Cancer. 1995; 31A(9):1531-7.
Score: 0.002
-
T cell V-gene usage in man in some normal and abnormal situations. Ann N Y Acad Sci. 1991 Dec 30; 636:9-19.
Score: 0.001
-
Dopamine agonists related to 3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzaz epi ne-7, 8-diol. 6-Position modifications. J Med Chem. 1987 Jan; 30(1):35-40.
Score: 0.001
-
T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2. Cell Immunol. 1986 Dec; 103(2):476-80.
Score: 0.001
-
Dopamine receptor agonists: 3-allyl-6-chloro-2,3,4,5-tetrahydro- 1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol and a series of related 3-benzazepines. J Med Chem. 1986 May; 29(5):733-40.
Score: 0.001
-
Immunofluorescent studies of human leukemic cells with antiserum to a murine leukemic virus (Rauscher strain). Blood. 1968 Mar; 31(3):381-7.
Score: 0.000